-+ 0.00%
-+ 0.00%
-+ 0.00%

NovaBridge reports 79% response rate at selected givastomig dose in Phase 1b trial

PUBT·10/25/2026 11:00:47
Listen to the news
NovaBridge reports 79% response rate at selected givastomig dose in Phase 1b trial
  • NovaBridge Biosciences presented updated Phase 1b results for givastomig at ESMO 2026, supporting its advancement toward registrational development.
  • Givastomig combined with nivolumab and chemotherapy showed durable clinical benefit in first-line metastatic gastroesophageal adenocarcinoma, including tumors with low CLDN18.2 expression.
  • Safety remained manageable, with no life-threatening or fatal treatment-related adverse events attributed to givastomig.
  • The totality of efficacy, safety and long-term follow-up findings supported selection of the 8 mg/kg dose for registrational development.
  • FDA alignment on a global Phase 3 study protocol strengthened the development pathway; givastomig also holds orphan drug and fast-track designations.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NovaBridge Biosciences published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610250700PRIMZONEFULLFEED9852348) on October 25, 2026, and is solely responsible for the information contained therein.